


Case 21301P

Page 2

In the Claims

Claims 1-36 are canceled.

37(Currently Amended). A compound of Formula I



wherein

~~a and b are independently 0 or 1;~~

m is independently 0,1 or 2;

R<sup>1</sup> is:

- 1) C<sub>2</sub>-C<sub>6</sub> alkenyl,
- 2) C<sub>2</sub>-C<sub>6</sub> alkynyl,
- 3) C<sub>1</sub>-C<sub>8</sub> alkyl,
- 4) (C=O)NR<sup>a</sup>R<sup>b</sup>,
- 5) (C=O)R<sup>c</sup>,
- 6) (C=O)OR<sup>c</sup>, or
- 7) heterocyclyl, said heterocyclyl is substituted with at least one substituent selected from:
  - a) C<sub>0</sub>-C<sub>6</sub> alkyl-(C=O)NR<sup>a</sup>R<sup>b</sup>,
  - b) C<sub>0</sub>-C<sub>6</sub> alkyl-SO<sub>m</sub>R<sup>d</sup>,
  - c) C<sub>0</sub>-C<sub>6</sub> alkyl-CO<sub>2</sub>R<sup>c</sup>,
  - d) C<sub>1</sub>-C<sub>6</sub> alkyl-OR<sup>c</sup>,
  - e) C<sub>1</sub>-C<sub>6</sub> alkyl-NR<sup>a</sup>R<sup>b</sup>, and
  - f) C<sub>0</sub>-C<sub>6</sub> alkyl-(C=O)-C<sub>0</sub>-C<sub>6</sub> alkyl-OR<sup>c</sup>;

R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are hydrogen;

R<sup>4</sup> is selected from:

- 1) C<sub>6</sub>-10 aryl,
- 2) C<sub>5</sub>-10 heterocyclyl, provided that R<sup>4</sup> is not pyrididonyl.

Case 21301P

Page 3

said aryl and heterocyclyl optionally substituted with at least one substituent selected from R<sup>b</sup>;

R<sup>a</sup> and R<sup>b</sup> independently are independently selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 3) C<sub>2</sub>-C<sub>6</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>6</sub> alkynyl,
- 5) C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 6) C<sub>6</sub>-10 aryl,
- 7) C<sub>5</sub>-10 heterocyclyl,
- 8) C<sub>0</sub>-C<sub>6</sub> alkyl-(C=O)NR<sup>a</sup>R<sup>b</sup>,
- 9) C<sub>0</sub>-C<sub>6</sub> alkyl-SO<sub>m</sub>R<sup>d</sup>,
- 10) C<sub>0</sub>-C<sub>6</sub> alkyl-CO<sub>2</sub>R<sup>c</sup>,
- 11) C<sub>0</sub>-C<sub>6</sub> alkyl-OR<sup>c</sup>,
- 12) C<sub>0</sub>-C<sub>6</sub> alkyl-NR<sup>a</sup>R<sup>b</sup>, and
- 13) C<sub>0</sub>-C<sub>6</sub> alkyl-(C=O)-C<sub>0</sub>-C<sub>6</sub> alkyl-OR<sup>c</sup>,

said alkyl, aryl and heterocyclyl are optionally substituted with at least one substituent selected from R<sup>d</sup>,

and wherein, when R<sup>a</sup> and R<sup>b</sup> are attached to a nitrogen within this definition, R<sup>a</sup> and R<sup>b</sup> are each independently selected from:

- a) H,
- b) unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkyl,
- c) unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

R<sup>c</sup> independently is:

- 1) H,
- 2) Unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkyl,
- 3) Unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub> alkenyl,
- 4) Unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub> alkynyl,
- 5) Unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 6) Unsubstituted or substituted C<sub>6</sub>-10 aryl, or
- 7) Unsubstituted or substituted C<sub>5</sub>-10 heterocyclyl;

said substitution being at least one substituent selected from R<sup>b</sup>;

Case 21301P

Page 4

R<sup>d</sup> independently is:

- 1) Unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkyl,
- 2) Unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub> alkenyl,
- 3) Unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub> alkynyl,
- 4) Unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 5) Unsubstituted or substituted C<sub>6</sub>-10 aryl, or
- 6) Unsubstituted or substituted C<sub>5</sub>-10 heterocyclyl;

said substitution being at least one substituent selected from R<sup>b</sup>;

or a pharmaceutically acceptable salt or stereoisomer thereof.

38(Previously Presented). The compound of claim 37, wherein R<sup>4</sup> is aryl, which is optionally substituted with at least one substituent selected from R<sup>b</sup>, or a pharmaceutically acceptable salt or stereoisomer thereof.

39(Previously Presented). A compound selected from:


6-(4-methoxy-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester;  
6-(4-methoxy-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid;  
6-(4-methoxy-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid amide;  
6-(4-methoxy-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carbonitrile;  
ethyl 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]nicotinate;  
5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-methylnicotinamide;  
N-ethyl-5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]nicotinamide;  
N-cyclopropyl-5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]nicotinamide;  
5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-propylnicotinamide;  
5-[6-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-methylnicotinamide;  
N-ethyl-5-[6-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]nicotinamide;  
5-[6-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-propylnicotinamide;  
N-cyclopropyl-5-(6-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)nicotinamide;  
N-propyl-5-(6-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)nicotinamide;

or a pharmaceutically acceptable salt or stereoisomer thereof.

40(Previously Presented). The compound according to claim 39 selected from:  
5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-methylnicotinamide


Case 21301P

Page 5




or a pharmaceutically acceptable salt or stereoisomer thereof.

41(Previously Presented). The compound according to claim 39 selected from:  
N-ethyl-5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]nicotinamide



or a pharmaceutically acceptable salt or stereoisomer thereof.

42(Previously Presented). The compound according to claim 39 selected from:  
N-cyclopropyl-5-(6-pyridin-4-ylpyrazolo [1,5-a]pyrimidin-3-yl)nicotinamide



or a pharmaceutically acceptable salt or stereoisomer thereof.

43(Previously Presented). A pharmaceutical composition which is  
comprised of a compound in accordance with claim 37 and a pharmaceutically acceptable  
carrier.